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Staphylococcus aureus was reported to be the 
commonest cause of all forms of neonatal sepsis in 
most Nigerian centres (35% in Sagamu, 36.2% in 
 2,6, 8Ile-Ife, and 45.5% in Abakaliki),  Gram-negative 
bacilli were mostly associated with early-onset 
sepsis. 
R I S K  FA C T O R S  F O R  N E O N ATA L 
INFECTIONS
Risk factors for early-onset sepsis include maternal 
genital tract colonization with GBS, maternal 
urinary tract infection, maternal fever during labour, 
pre-labour rupture of foetal membranes for more 
than 18 hours, prolonged rupture of foetal 
membrane for more than 18 hours and 
 11
chorioamnionitis.  Thus, the American Academy of 
12
Pediatrics  stipulated that routine screening of 
pregnant women with risk factors for GBS 
colonization (previous infant with GBS disease, 
GBS bacteriuria during pregnancy and preterm 
birth) should be done in the third trimester (between 
35 and 37 weeks) to institute prenatal antibiotic 
therapy. Women with confirmed GBS colonization 
should have intrapartum penicillin to prevent GBS 
disease in the newborn. When GBS colonization is 
not confirmed, intrapartum penicillin should still be 
administered in the presence of intrapartum fever or 
prolonged rupture of foetal membranes. The former 
prevents 90% of potential neonatal GBS disease 
while the latter prevents about 69% of potential 
 12 GBS cases. Obviously, this protocol may not be 
applicable in this environment where GBS is 
reportedly rare.
Risk factors for late-onset sepsis include very low 
birth weight, prolonged hospitalization, invasive 





Babies born with perinatal risk factors for sepsis 
may be symptomatic (called Probable Sepsis) or 
may be asymptomatic (Presumed Sepsis) at or soon 
Neonatal infections are major contributors to 
neonatal morbidity and mortality in the developing 
1-3
world.  Although, the incidence of sepsis is 
generally low, it may be associated with significant 
mortality. In some parts of the developed world, a 
 4prevalence of 6.6/1000 live births was reported,  
and mortality associated with sepsis may be as high 
 5as 50% in untreated cases.  The prevalence of sepsis 
among Nigerian newborn babies was 22.9/1000 live 
births in Ile – Ife, 22.5/1000 live births in Sagamu 
6 - 8and 7.98/1000 live births in Abakaliki.   
Neonatal sepsis is classified as Early-onset if 
features of sepsis develop within 48 hours of life. 
This usually results from perinatal exposure to 
9
microbes within the birth canal.  In Late-onset 
sepsis features begin to manifest after 48 hours of 
b i r th  usua l ly  fo l lowing  envi ronmenta l  
contamination either within the community 
(acquired from care givers) or within the hospital 
(acquired from the nursery staff and hospital 
equipments).
AETIOLOGY
In the developed world, 80% of severe neonatal 
infections are caused by Group B Streptococcus 
(GBS), Coagulase negative Staphylococcus 
(CONS) and Escherichia coli. The remaining 20% 
are due to infection with Pseudomonas aeruginosa, 
other Gram-negative bacilli (Klebsiella, Proteus, 
Enterobacter), Staphylococcus aureus and Listeria 
10
monocytogenes.   
 2
In Sagamu,  Staphylococcus aureus, CONS, 
Klebsiella and unclassified Coliforms were the 
leading causes of neonatal sepsis. Similar patterns 
6, 8
were reported in Ile-Ife and Abakaliki.  Extensive 
literature search suggests that GBS is a rare cause of 
early-onset sepsis in the tropics including Nigeria. 
No case of GBS infection was reported among 127 
babies screened for sepsis in Sagamu while only one 
case of GBS was identified among 138 babies in 
7, 8Abakaliki.  Similarly, Listeria monocytogenes was 
not reported in these local studies. Although, 
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now to the rescue. Other aminoglycosides used in 
situations of resistance to Gentamicin include 
Tobramycin,Netilmicin,Amikacin and Kanamycin. 
However, the main concern about this class of drugs 
is the risk of nephrotoxicity and ototoxicity, 
particularly among preterm infants.  
These recommendations do not show significant 
variation from the local findings on antibiotic 
sensitivity pattern of the aetiologies of neonatal 
sepsis. Gentamicin was recommended in Ile-Ife, 
6 - 8Ilorin and Abakaliki,  but the overall sensitivity of 
63 % of all the gram-negative organisms to 
Gentamicin in the Sagamu study indicated a 
declining trend in the sensitivity of these organisms 
to gentamicin. Remarkable resistance against the 
natural and synthetic Penicillins had been reported 
in most Nigerian centres, so, the combination of a 
second generation Cephalosporin (commonly 
Cefuroxime) and Gentamicin are used empirically 
for early-onset disease while Ceftriaxone with 
Gentamicin is used for late-onset disease. 
These drugs are administered intravenously. 
Intramuscular administration is equally reliable and 
effective but carries the risk of muscle and nerve 
damage. However, there is no place for oral 
antibiotic use in neonatal sepsis except for urinary 
tract infections and superficial skin infections. For 
suspected sepsis, antibiotics must be administered 
until the bacteriological reports are available. 
However, the drugs can be stopped after 48 hours if 
the clinical signs improve and the blood culture 
reports are negative. If the blood culture reports are 
positive, the treatment must be tailored to the 
antibiotic sensitivity pattern of the isolate and must 
be continued for 10 to 14 days. When meningitis is 
present, the treatment may be continued for at least 
21 days and for up to 4 weeks in the presence of 
osteo-articular infections.   
It is important to monitor the plasma levels of 
aminoglycosides to avoid toxicity but this is not 
necessary with Cephalosporins and Penicillins. The 
plasma levels of aminoglycoside should be 
determined just before the next dose (trough) and 1-
hour after the last dose (peak) to assess the efficacy 
of treatment and the risk of toxicity. The trough for 
Gentamicin should be <2µg/ml. When the trough is 
high, the dose frequency should be decreased to 
once in 36 hours or 48 hours to avoid toxicity and 
when it is low, the dose frequency should be 
after birth. Most commonly, such babies are 
asymptomatic and may develop clinical evidences 
of sepsis rapidly. Sepsis is suspected in the presence 
of suggestive clinical or laboratory features which 
may warrant antibiotic therapy. It is proven or 
confirmed with positive bacteriological culture of 
blood, urine or cerebrospinal fluid. 
Clinical features suggestive of sepsis include 
temperature instability, respiratory distress, 
vomiting, diarrhoea, poor feeding intestinal ileus, 
lethargy, irritability, seizures, abnormal muscle 
tone, loss of primitive reflexes, abnormal cry and 
poor skin colour. Suggestive laboratory evidences 
of sepsis include abnormal leucocytes count (low or 
high), left shift in differential leucocytes count, 
elevated band/neutrophil ratio, thrombocytopaenia 
and elevated C-Reactive protein.
MANAGEMENT
Antibiotics
There is a universal consensus on the need to 
manage infants with suspected or proven sepsis with 
broad spectrum antibiotics. It is recommended that 
newborn infants with suspected sepsis should have 
initial sepsis screen (blood culture, swabs culture) 
and parenteral antibiotics should be empirically 
commenced. Subsequent management depends on 
the clinical picture and the result of bacteriological 
screening. Nevertheless, the initial choice of 
antibiotics depends on the local prevalence pattern 
of organisms and pattern of local antibiotic 
resistance. For example, although, penicillin is the 
drug of choice for GBS but there are reports that the 
widespread practice of administering intrapartum 
penicillin for women colonized with GBS has led to 
increased r isk  of  Methici l l in-Resis tant  
 13
Staphylococcus aureus (MRSA).
Traditionally, a combination of penicillin with 
aminoglycoside is used in the treatment of early-
onset sepsis prior to the availability of 
bacteriological reports. Penicillin is meant to treat 
GBS and other Gram-positive organisms while the 
aminoglycoside is meant to treat coliforms. On the 
other hand, a combination of Flucloxacillin and 
Gentamicin is used to treat late-onset disease. These 
drugs treat Staphylococcus and coliforms. 
Flucloxacillin may be replaced with Vancomycin 
for Staphylococcus strains and Piperacillin for 
Pseudomonas. Due to widespread antibiotic 
resistance, the third-generation Cephalosporins are 
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developed clinical evidences of sepsis. Gerard  
also studied 67 babies whose mothers had 
confirmed GBS colonization between 32 and 34 
weeks of gestation. Twenty-nine babies received 
prophylactic penicillin and sepsis screen while the 
remaining 38 were not put on antibiotic treatment 
but had similar sepsis screening. When sepsis was 
confirmed, antibiotics were commenced and 
administered for 7 days.
19Gerard  reported that none of the babies developed 
sepsis and no mortality occurred. On the other hand, 
 18Wolf  reported that none of the babies on 
prophylactic treatment developed sepsis while 4 out 
of the 25 babies who did not receive antibiotic 
prophylaxis developed confirmed sepsis. Similar to 
Gerard's report, no mortality occurred.
There was no statistically significant evidence that 
prophylactic treatment prevents the development of 
sepsis since only 4 out of a total of 116 babies 
developed clinical evidences of sepsis. Similarly, 
there has been no sufficient evidence that even 
intrapartum antibiotic treatment of mothers with 
prolonged membrane rupture at term improves 
 20neonatal outcome.
Research Question: Does combination antibiotic 
therapy have any benefit over antibiotic 
 21monotherapy in the treatment of neonatal sepsis?
In randomized and quasi-randomized controlled 
studies comparing antibiotic regimens for the 
treatment of early neonatal sepsis, term and preterm 
newborns babies from birth to 48 hours of age 
requiring treatment for suspected neonatal sepsis 
were recruited. Although, 15 eligible studies were 
identified only 2 studies were reviewed. No study of 
antibiotic monotherapy versus monotherapy or 
combination antibiotic therapy versus combination 
antibiotic therapy was found. The 2 selected studies 
compared ant ib iot ic  monotherapy wi th  
combination antibiotic therapy.
 22Miall-Allen  compared Timentin (Ticarcillin and 
clavulanate) monotherapy with combination 
therapy of Piperacillin and Gentamicin among 72 
 23babies while Snelling  compared Ceftazidime 
monotherapy with Benzylpenicil l in and 
Gentamicin combination among 55 babies.
23Although, Snelling  reported no mortality in both 
22groups, Miall-Allen  reported 3 deaths in the 
increased to once in 8 hours for better efficacy. 
Similarly, the peak for Gentamicin should be 6-
10µg/ml. The dose must be reduced to avoid toxicity 
when the peak is high and when the peak is low, the 
 14 - 16
dose must necessarily be increased for efficacy.
Despite these developments and the various 
empirical modifications in treatment modalities, the 
mortality in neonatal sepsis remains significantly 
high in many parts of the world. Thus highlighting 
the need for improved and optimal antibiotic 
treatment of neonatal sepsis with the ultimate goal 
of reducing the morbidity and mortality associated 
with neonatal sepsis. This challenge has prompted 
several researches though with conflicting results. 
Therefore, systematic reviews of these randomized 
controlled studies which were carried out from the 
sixties till date were conducted to determine the 
statistical significance of the various findings in 
order to derive their clinical applicability.    
These developments have not affected the global 
consensus that preterm infants with perinatal risk 
factors, irrespective of the absence of suggestive 
clinical features, should be commenced on 
empirical antibiotics until cultures are negative, in 
10any way. 
Research Question: Should term asymptomatic 
babies with perinatal risk factors for sepsis be 
commenced on prophylactic or selective 
17antibiotics? 
In randomized controlled trials of term 
asymptomatic babies whose mothers were screened 
for GBS colonization in pregnancy and term 
asymptomatic babies born to mothers with other 
risk factors for neonatal sepsis, the considered risk 
factors were intrapartum fever>/=38C, prelabour 
rupture of membrane>18hrs, prolonged rupture of 
membrane >18 hrs, chorioamnionitis, UTI detected 
during labour and confirmed genital colonization at 
35-37 weeks of gestation without intrapartum 
antibiotic treatment.
Six eligible studies were identified in a systematic 
review but only two met the criteria for meta-
18analysis. Wolf  studied 49 babies whose mothers 
had prolonged rupture of membranes in 
Johannesburg, South Africa. Twenty four babies had 
penicillin and kanamycin immediately after birth 
and for 7 days while the remaining 25 did not 
receive prophylactic antibiotics unless they 
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5ug/ml than multiple doses regimen. Similarly, 
there was a statistically significant difference 
indicating that once-a-day regimen is associated 
with less failures to achieve troughs levels of < 
2ug/ml than multiple doses a day regimen. These 
implied that there were no treatment failures in 
either the once-a-day or multiple doses a day 
regimen but there were significantly higher peak 
levels in the once-a-day regimen and significantly 
lower trough levels with once-a-day regimen. All 
these applied even when Gentamicin was given 
intramuscularly or intravenously. 
Only one study reported hearing impairment in both 
groups of treatment but meta-analysis did not show 
any significant difference in both groups in terms of 
nephrotoxicity caused by Gentamicin.
In conclusion, although there was no difference in 
the clinical efficacy of the two Gentamicin dose 
regimen, the once-a-day regimen has many 
pharmacokinetic advantages over the multiple 
doses regimen thus making it safer for use. It is also 
noteworthy that preterms <32 weeks in both groups 
showed high trough levels probably because of 
lower GFR, hence, even once-a-day gentamicin 
dose may be toxic in these babies. Therefore, it is 
suggested that once in 36 hours or once in 48 hours 
gentamicin dose may be appropriate for this group 
  25, 26of babies.
Adjuvant therapies
Immunotherapy may be used to improve the 
survival of newborn infants who are also on 
antibiotic therapy. This may be in form of 
i n t r a v e n o u s  I m m u n o g l o b u l i n  ( I V I G )  
administration, Granulocytes transfusion or 
administration of Granulocyte-Colony Stimulating 
Factor (G-CSF) and Granulocyte-Macrophages 
Colony Stimulating Factor (GM-CSF). Maternal 
transport of immunoglobulin to the foetus occurs 
after 32 weeks of gestation and endogenous 
synthesis does not begin until 24 weeks after birth. 
Therefore, it is postulated that IVIG provides 
Immunoglobulin G which binds to cell surface 
receptors, provide opsonic activity, activate 
complements and promote antibody dependent 
 27cytotoxicity.  IVIG is used prophylactically 
(0.5g/kg weekly for 4 to 6 weeks) to prevent late-
onset nosocomial infections in VLBW where it has 
been shown to significantly reduce sepsis but not 
 28
mortality from sepsis.  It may also be used 
Timentin monotherapy group and 5 deaths in the 
Piperacillin and Gentamicin group. However, meta-
analysis did not suggest a statistically significant 
difference in mortality in both groups. Similarly, 
 23
Snelling  reported no case of treatment failure in 
 22
both groups but Miall-Allen  reported 2 cases of 
treatment failure in the monotherapy group and 2 
treatment failures in the combination therapy group. 
Meta-analysis did not show any statistically 
significant difference in the occurrence of treatment 
failures. Interestingly, none of the studies reported 
resistance of organisms to the antibiotics used.
Therefore, there is, as at present, no evidence that 
combination antibiotic therapies are more effective 
in the treatment of neonatal sepsis. It is also 
noteworthy that there are no recent similar 
randomized controlled trials. The aforementioned 
reviewed studies were done more than two decades 
ago and antibiotic resistance pattern could have 
changed remarkably in most neonatal settings since 
then. There are also no separate trials on antibiotic 
treatment of late-onset sepsis. Definitely, more 
randomized controlled trials are required to 
compare antibiotic monotherapies separately and 
various combination therapies separately.
Research Question: Do multiple gentamicin doses 
have any benefit over single gentamicin dose in the 
 24treatment of neonatal sepsis?
In randomized and quasi-randomized controlled 
trials comparing a single dose per day and multiple 
doses per day regimen of Gentamicin in the 
treatment of neonatal sepsis, newborns with 
suspected or proven sepsis commenced on 
Gentamicin were studied. In all, 24 eligible trials 
were identified but only 11 (574 babies) were 
selected for review. All these were done between 
1999 and 2004 in North America, India, Thailand, 
Germany, Spain and Australia. In all these studies, 
intravenous infusion of Gentamicin was used except 
one that used bolus over one minute. Two studies 
also used a combination of intravenous infusion and 
intramuscular Gentamicin. The dose used in all the 
studies was 4-5mg/kg/day either as single dose or 
multiple doses. 
Although, meta-analysis did not show any 
significant difference in clinical efficacy (i.e 
clearance of proven sepsis) between the two groups, 
there was significant difference indicating that 
once-a-day regimen was associated with less 
failures of attainment of peak levels of at least 
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the small number of the babies studied) to prove that 
the use of IVIG should be routine in neonatal sepsis.
Research Quest ion: Does Granulocyte  
 33
transfusion reduce mortality in neonatal sepsis?
Four small randomized controlled studies involving 
newborn infants with suspected or proven sepsis 
and neutropenia and were on antibiotics were 
selected for review. Three of the selected trials (44 
babies) compared granulocytes transfusion with 
placebo while the last one (35 babies) used 
granulocyte transfusion versus IVIG. 
The comparison of granulocyte transfusion with 
placebo revealed no significant difference in the 
mortality of both term and preterm with early or late 
onset sepsis. While there was no reduction in all-
cause mortality when buffy coat transfusion is used, 
there was a reduction in all-cause mortality when 
leukophoresis-derived granulocytes were 
transfused. There was also no reduction in all-cause 
mortality when the dose of Granulocytes used was 
9 9
less than 0.5 × 10 /kg or greater than 0.5 × 10 /kg. 
However, there was a significant reduction in all-
cause mortality with granulocyte transfusion 
compared with IVIG. Although no adverse effect of 
granulocyte transfusion (Graft-Versus-Host 
Disease) was reported in all the trials, the risk of 
transmission of infections like HIV, Hepatitis and 
Cytomegalovirus, though not negligible, may be 
significantly reduced with irradiation of blood prior 
to the harvest of granulocytes. 
Due to the small number of babies studied, it is 
difficult to support or refute routine use of 
granulocytes transfusion in neonatal sepsis hence, 
larger randomized, controlled and blinded studies 
are required.
Research Question: Do G-CSF and GM-CSF 
prevent neonatal sepsis and reduce mortality in 
34
suspected or proven neonatal sepsis? 
Using 7 small treatment studies involving 332 
babies, analysis of the use of G-CSF and GM-CSF 
was grouped into 3: treatment studies, prophylaxis 
studies and toxicity studies. Six studies used G-CSF 
for treatment while 5 studies used GM-CSF for both 
prophylaxis and treatment.
In the treatment studies, no significant reduction in 
mortality was reported babies treated between day 1 
and 14 and between day 15 and 28. Indeed, only one 
therapeutically (0.5g/kg daily for four days) as an 
adjunct to antibiotics in all babies with suspected or 
proven sepsis.  
Newborns have immature granulopoiesis and this 
predisposes to infections which in turn deplete the 
neutrophil storage pool in the bone marrow and 
neutropenia (defined as neutrophil count 
<1700/µL). The occurrence of neutropenia 
 29increases the risk of mortality in neonatal sepsis.  
Thus, granulocyte transfusion prevents and treats 
sepsis-associated neutropenia and ultimately 
reduces the risk of mortality. These cells are 
prepared in concentrates form for transfusion either 
following leukophoresis or centrifugation of whole 
blood to yield buffy coat. The latter is easier and 
faster but it yields a lower dose of neutrophils 
compared to the former method. Therefore, buffy 
coat may appear to be less-effective in the reduction 
of mortality associated with sepsis than 
granulocytes  concentra tes  prepared by 
 30
leukophoresis.   
The G-CSF and GM-CSF are natural cytokines 
which boost the potent antibacterial functions of 
neutrophils and monocytes. They may be used 
prophylactically to prevent sepsis by stimulating 
neutrophil production and increasing the 
bactericidal actions of the neutrophils and 
 31monocytes in circulation.  These therapies appear 
to hold a lot of promise for the optimal prevention 
and treatment of neonatal sepsis.
Research Quest ion:  Does Intravenous 
Immunoglobulin reduce mortality in neonatal 
32
sepsis? 
Using randomized and quasi-randomized 
controlled trials involving newborns with suspected 
or proven infections, the effect of IVIG on mortality 
was assessed. A total of 9 studies (involving 553 
babies) conducted in India, Mexico, Saudi Arabia, 
Switzerland, Taiwan, Turkey and US were selected. 
In all these IVIG was compared with placebo in 
babies with suspected or proven sepsis. For 
suspected sepsis, IVIG caused reduction in 
mortality with borderline statistical significance 
while it caused significant reduction in mortality in 
proven sepsis. IVIG use was also associated with 
significant reduction in duration of hospital stay for 
term babies but not for preterm babies. No adverse 
effect of IVIG was reported in all the studies. It was 
concluded that there is insufficient evidence (due to 
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babies with presumed sepsis, basic sepsis screening 
(blood culture) and close observation for suggestive 
clinical features are adequate for 48 hours when 
laboratory report will be available. If clinical signs 
develop even before the availability of laboratory 
report, empirical antibiotics should be commenced 
and continued till the signs improve or the blood 
culture report is negative. Preterm infants with 
presumed sepsis should be commenced on 
prophylactic antibiotics once sepsis screening is 
completed.  
Where they are available, adjuvant therapies, in 
form of Granulocytes transfusion, IVIG 
administration and CSF administration may be 
helpful in reducing the burden of neonatal sepsis in 
the developing world. Large randomized controlled 
studies are required to determine the best antibiotic 
regimen in the treatment of neonatal sepsis and 
establish the efficacy and safety of these adjuvant 
therapies in neonatal sepsis.  
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